# Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)

> **NCT00609401** · PHASE2 · COMPLETED · sponsor: **Italian Trial in Medical Oncology** · enrollment: 90 (actual)

## Conditions studied

- Metastatic Disease
- Renal Cell Carcinoma

## Interventions

- **DRUG:** Nexavar (Sorafenib)
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT00609401
- **Lead sponsor:** Italian Trial in Medical Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-05
- **Final completion:** 2008-05
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2009-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609401, "Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00609401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*